Leptin replacement therapy in the management of lipodystrophy syndromes
Annales d'Endocrinologie · 2024-06 · 85 (3) · 201-204
DOI: 10.1016/j.ando.2024.05.022 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annales d'Endocrinologie, 2024-06. Verfasst von Corinne Vigouroux und 2 weiteren Autor:innen. Beteiligte Einrichtung: Service d'endocrinologie, diabétologie et endocrinologie de la reproduction, centre national de référence des pathologies rares de l'insulino-secréti…. Hauptthemen laut MEDLINE: Leptin, Lipodystrophy, Hormone Replacement Therapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Lipodystrophy syndromes are rare diseases of genetic or acquired origin, characterized by quantitative and qualitative defects in adipose tissue. The metabolic consequences of lipodystrophy syndromes, such as insulin resistant diabetes, hypertriglyceridemia and hepatic steatosis, are frequently very difficult to treat, resulting in significant risks of acute and/or chronic complications and of decreased quality of life. The production of leptin by lipodystrophic adipose tissue is decreased, more severely in generalized forms of lipodystrophy, where adipose tissue is absent from almost all body fat depots, than in partial forms of the disease, where lipoatrophy affects only some parts of the body and can be associated with increased body fat in other anatomical regions. Several lines of evidence in preclinical and clinical models have shown that leptin replacement therapy could improve the metabolic complications of lipodystrophy syndromes. Metreleptin, a recombinant leptin analogue, was approved as an orphan drug to treat the metabolic complications of leptin deficiency in patients with generalized lipodystrophy in the USA or with either generalized or partial lipodystrophy in Japan and Europe. In this brief review, we will discuss the benefits and limitations of this therapy, and the new expectations arising from the recent development of a therapeutic monoclonal antibody able to activate the leptin receptor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'endocrinologie, diabétologie et endocrinologie de la reproduction, centre national de référence des pathologies rares de l'insulino-secrétion et de l'insulino-sensibilité (PRISIS), hôpital Saint-Antoine, Assis…
- Centre de recherche Saint-Antoine, institut hospitalo-universitaire de cardio-métabolisme et nutrition (ICAN), Sorbonne université, Inserm UMR_S 938, Paris, France; Service endocrinologie, diabétologie, nutrition, centr…
Zitieren
APA
Vigouroux, C., Mosbah, H., & Vatier, C. (2024). Leptin replacement therapy in the management of lipodystrophy syndromes. Annales d'Endocrinologie, 85(3), 201-204. https://doi.org/10.1016/j.ando.2024.05.022
Vancouver
Vigouroux C, Mosbah H, Vatier C. Leptin replacement therapy in the management of lipodystrophy syndromes. Annales d'Endocrinologie. 2024;85(3):201-204. doi:10.1016/j.ando.2024.05.022
BibTeX
@article{Vigouroux2024,
author = {Vigouroux, Corinne and Mosbah, Héléna and Vatier, Camille},
title = {Leptin replacement therapy in the management of lipodystrophy syndromes},
journal = {Annales d'Endocrinologie},
year = {2024},
volume = {85},
number = {3},
pages = {201--204},
doi = {10.1016/j.ando.2024.05.022}
}
EUVIMED